ESMO 2026 Opens in Madrid With Phase 3 Readouts in Melanoma, Endometrial, Gastric and Bladder Cancer

Cancer Research UK's ESMO 2026 round-up (Oct 23) lists INTerpath-001, where the personalised mRNA vaccine intismeran plus pembrolizumab cut risk of recurrence or death by 42% over two years versus pembrolizumab alone in resected stage 2-4 melanoma; TroFuse-005, where sacituzumab tirumotecan lowered progression risk by 41% and death risk by 32% in previously treated endometrial cancer; and VOLGA, where durvalumab plus enfortumab vedotin gave 78% versus 69% overall survival in cisplatin-ineligible muscle-invasive bladder cancer. Results are as presented or announced; long-term survival follow-up is still needed.